Image Source: Zacks Investment Research As reported by partner AbbVie ABBV, Ironwood’s sole marketed product — Linzess (linaclotide) — generated net sales of almost $250.2 million in the ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Investing in the biotech sphere isn’t for the faint of heart, and you ...

There’s a 1-1 tie in the U.S. Circuit Courts of Appeal on the validity of “overtime gap time claims” under the Fair Labor Standards Act.

Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced it will host its first quarter 2024 investor update conference ...

Since 1926, dividends have contributed approximately 32% of the total return for the S&P 500, while capital appreciations ...

Two of Allergan’s former sales representatives accused the pharmaceutical manufacturer of violating the False Claims Act and Anti-Kickback Statute by using a “speaker program” to give physicians ...

Ironwood Pharmaceuticals plans to buy a Swiss biotech for $1 billion as the Boston drug firm seeks to strengthen its focus on treatments for gastrointestinal diseases. Ironwood, which makes the ...

They might prescribe Amitiza (lubiprostone), Linzess (linaclotide), or Trulance (plecanatide). Constipation may require surgery in severe cases to correct a blockage or tear or, rarely ...

Linzess collaboration revenues drive the top line. SAN DIEGO, November 09, 2023--MEI Pharma, Inc. (Nasdaq: MEIP), a clinical-stage pharmaceutical company evaluating novel drug candidates to ...